Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
piotr wysocki
Apr 21, 2024, 17:24 |
Insight
Piotr Wysocki: Only biliary tract and ovarian advanced cancer patients seem to benefit from next-generation sequencing
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 20, 2024, 18:21 |
Insight
Piotr Wysocki: Pregnancy and anticancer immunotherapy - How safe is accidental exposure to immune checkpoint inhibitors?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 19, 2024, 20:03 |
Insight
Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients - underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 17, 2024, 18:37 |
Blog
Piotr Wysocki: A new, broad-spectrum RAS-GTP inhibitor holds promise in pancreatic cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 16, 2024, 11:36 |
Insight
Piotr Wysocki: Rechallenge with anti-EGFR antibodies is a feasible and safe strategy in refractory metastatic colorectal cancer patients with RAS/BRAFwt ctDNA
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 16, 2024, 11:25 |
Drugs
Piotr Wysocki: Adjuvant olaparib improves outcomes of breast cancer patients with germinal BRCA1/2 mutations at the cost of slightly decreased quality of life
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 15, 2024, 14:41 |
Drugs
Piotr Wysocki: The [177Lu]Lu-PSMA-617 plus enzalutamide combination is active and safe in mCRPC patients, but is it really an option for first-line treatment?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 14, 2024, 03:52 |
Drugs
Piotr Wysocki: CLEAR trial – another study demonstrating that Immunotherapy and TKI combination should not be routinely recommended to favorable-risk RCC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 12:10 |
Insight
Piotr Wysocki: Cetuximab monotherapy maintenance after FOLFIRI may not be the optimal choice but can be considered in selected mCRC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 11:46 |
Drugs
Piotr Wysocki: Adjuvant treatment with Alectinib in resected ALK-positive non-small cell lung cancer – interim analysis results of ALINA trial published in NEJM
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University Hospital,…
5
6
7
8
9
All:
112
Posts:
61 - 70
Dikembe Mutombo: In Memory of Basketball Icon Who Died at 58 Battling Brain Cancer
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7
César Milstein - The Father of Modern Immunology
ESTRO: Everything You Need to Know About European Society for Radiotherapy and Oncology
Jane Fonda Breast Cancer and Non-Hodgkin Lymphoma: How She Went Against, How She Survived, and More
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube